Investors in Tvardi Therapeutics, Inc. (TVRD) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today

Core Insights - Tvardi Therapeutics, Inc. is under investigation for possible violations of federal securities laws following disappointing results from its Phase 2 REVERT study of TTI-101, a STAT3 inhibitor for idiopathic pulmonary fibrosis (IPF) [1][2] - The Phase 2 study did not meet its goals, with no statistically significant differences observed between the treatment and placebo groups, and a high discontinuation rate of over 56% in treatment arms compared to 10.3% in the placebo group [2] - Following the announcement of the study results, Tvardi's stock price dropped significantly by $34.91, closing at $6.69 per share [3] Company Overview - Tvardi Therapeutics is focused on developing treatments for serious diseases, specifically targeting idiopathic pulmonary fibrosis with its drug TTI-101 [2] - The company has faced challenges in its clinical trials, as indicated by the recent Phase 2 study results [2] Legal Context - Levi & Korsinsky LLP, a recognized securities litigation firm, has initiated an investigation into Tvardi Therapeutics, indicating potential legal ramifications for the company [1][4] - The firm has a strong track record in securities litigation, having secured significant settlements for shareholders in the past [4]